NCT05796973 (MOVES) is a Phase 3 clinical trial of Guided physical exercise in Prostate Cancer, sponsored by Tampere University Hospital.

Who is sponsoring NCT05796973?

NCT05796973 is sponsored by Tampere University Hospital.

What drugs are being tested in NCT05796973?

Interventions in NCT05796973: Guided physical exercise, Atorvastatin, Independent exercise.

What condition does NCT05796973 study?

NCT05796973 studies Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer, Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Metastatic Ovarian Cancer, Metastatic Ovary Cancer.

Is NCT05796973 still recruiting?

NCT05796973 is currently recruiting now. Last updated 27 June 2025.

Last reviewed 2025-06-27 · How we verify

NCT05796973: MOVES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Measuring Oncological Value of Exercise and Statin

Recruiting now Phase 3 Last updated 27 June 2025

What this trial tests

Phase 3 trial testing Guided physical exercise in Prostate Cancer in 240 participants. Currently enrolling.

Timeline

31 March 2023

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	Tampere University Hospital
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	240
Start date	31 March 2023
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across Finland

Drugs / interventions tested

Guided physical exercise
Atorvastatin (atorvastatin) — full drug profile →
Independent exercise

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Breast Cancer — all drugs for Breast Cancer →
Kidney Cancer — all drugs for Kidney Cancer →
Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Tampere University Hospital

Who can join

Adults 18 to 99, any sex, with Prostate Cancer or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Statins as anti-tumor agents: A paradigm for repurposed drugs.
Tripathi S, Gupta E, Galande S. · · 2024 · cited 34× · PMID 38711272 · DOI 10.1002/cnr2.2078
Ovarian cancer targeted therapy: current landscape and future challenges.
Wang G, Yang H, Wang Y, Qin J. · · 2025 · cited 13× · PMID 40395324 · DOI 10.3389/fonc.2025.1535235
Is Exercise During Androgen Deprivation Therapy Effective and Safe? A Randomized Controlled Trial.
Rantaniemi L, Jussila I, Siltari A, Ahtiainen JP, et al · · 2025 · cited 1× · PMID 40481694 · DOI 10.1111/sms.70084

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Tampere University Hospital trials

Trials by the same sponsor.

NCT07315568 — Couples and Microbial Diversity · not yet recruiting
NCT07128992 — Need-driven Treatment of the Patients With Type 1 Diabetes · not yet recruiting
NCT07042139 — No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older · NA · recruiting
NCT07528833 — Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain · NA · recruiting
NCT06711796 — Measurement of Muscle Relaxation of the Hand in From Two Muscles and Two Hand Positions · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05796973 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tampere University Hospital
Last refreshed: 27 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05796973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing